Navigation Links
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
Date:9/24/2008

e (SAD) Study in Healthy Volunteers (Poster #1871): ITMN-191 was safe and well tolerated when given as a single dose to healthy adults in a range of doses from 2mg to 1600mg. Adverse events were generally mild and transient and were similar between treatment groups, with the exception of a higher frequency of mild and transient diarrhea and abdominal pain in the ITMN-191 group at the highest tested dose (1600mg). The pharmacokinetics of ITMN-191 were linear over the dose range of 100mg to 800mg. Co-administration of ITMN-191 with food increased the expected trough and AUC by 40-50% compared with administration of ITMN-191 without food. This "food effect" enabled InterMune and Roche to explore a lower range of doses of ITMN-191 in subsequent clinical studies than was previously planned.

-- A Phase 1b Monotherapy Multiple-Ascending-Dose (MAD) Study in HCV Genotype 1 Patients (Poster #1847): ITMN-191 was administered as mono-therapy for 14 days to four cohorts of treatment-naive patients infected with HCV genotype 1. Multiple ascending doses were examined up to a total daily dose of 600mg. The safety and tolerability of ITMN-191 were excellent. Adverse events were generally mild and transient, with no evidence of clinically significant laboratory abnormalities or ECG changes. When ITMN-191 was administered every eight or twelve hours, viral kinetic results were very competitive with those of other direct antiviral compounds studied in similar experiments.

The MAD study also included one exploratory cohort of ITMN-191 given as mono-therapy for 14 days to strictly defined non-responders: HCV genotype 1 patients who had failed to achieve a 2.0 log10 reduction in HCV RNA with prior standard-of-care treatment, or who still had detectable HCV RNA after 24 weeks of treatment. At the one dose studied of 300mg given every 12 hours, ITMN-191 delivered a median reduction of HCV RNA at study day 14 of 2.5 log10. The results from this initial exploratory cohort in non
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
2. InterMune to Present at Canaccord Adams Conference
3. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
4. InterMune to Present at BMO Healthcare Conference
5. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
6. InterMune to Present at Jefferies Healthcare Conference
7. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
8. InterMune to Present at Citigroup Healthcare Conference
9. InterMune to Present at Bank of America Health Care Conference
10. InterMune to Present at Deutsche Bank Health Care Conference
11. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... “This kit has an improved extraction efficiency and ... 150 ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for ... owners and USDA-GIPSA inspection agencies that have a need to ... place in a matter of minutes with nothing but our ... feed and grain before accepting it, but they no longer ...
(Date:8/28/2014)... month, executives from clinical trial marketing firm BBK Worldwide will ... Patient-Centered Clinical Trials 2014 , to be held at the ... 4-5. Patient recruitment experts Bonnie A. Brescia , ... insights on the benefits of employing an effective patient engagement ... to mobile apps – can be used to drive study ...
(Date:8/28/2014)... (PRWEB) August 27, 2014 Scientists, researchers, ... for SPIE Laser Damage 2014 symposium. Marking ... for high-power lasers will run 14-17 September. The event ... optics and photonics . , The premier conference for ... laser damage to optical materials will engage researchers and ...
(Date:8/28/2014)... Whitehouse Laboratories is excited to announce ... PTI Inspection Systems that will enable it ... art leak testing method development and validation programs using ... As part of this agreement, Whitehouse Labs has taken ... Instrument developed and manufactured by PTI. The HVLD ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3
... FRANCISCO, Calif., Dec. 8 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... chief executive officer, will participate in a panel,discussion at the ... and Targets for Inflammation and Rheumatology", will take,place on Wednesday, ... Times,Square Hotel in New York City. , ...
... MINNEAPOLIS, Dec. 8 ATS Medical, Inc.,(Nasdaq: ATSI ... today announced it has received FDA clearance for the,marketing of ... tab,material supplier and an improved valve holder accessory device. , ... ) , While the ...
... When it comes to the world of the very, very ... and its capacity to alter the fundamentals of nature, it ... In a report published today (Dec. 7) in the journal ... and Europe reveal a sharp contrast in the perception that ...
Cached Biology Technology:ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 2ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 3For nano, religion in US dictates a wary view 2For nano, religion in US dictates a wary view 3
(Date:8/28/2014)... of new roads will be built worldwide by 2050. ... wildernesses, where they bring an influx of destructive loggers, ... study has created a ,global roadmap, for prioritising road ... competing demands of development and environmental protection. , The ... that natural importance of ecosystems and a ,road-benefits, layer ...
(Date:8/28/2014)... the world to Global Warming, has called for atmospheric ... He says that Carbon Capture, combined with limits on ... global warming getting out of control over the next ... the call during his presentation to the International Carbon ... to discuss Carbon Capture and Storage. , He ...
(Date:8/28/2014)... assigned a number of 435-million-year-old fossils to a ... in shallow marine habitats and were far less ... , Before they sank to the bottom ... some 435 million years ago, these arthropods preyed ... although they were not exactly inconspicuous, possessing a ...
Breaking Biology News(10 mins):Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3Global warming pioneer calls for CO2 to be taken from atmosphere and stored underground 2Paleontology: Oldest representative of a weird arthropod group 2
... is poised to become the first example of a ... a major threat to endangered wildlife that authorities are ... found only in Iran, is considered Critically Endangered and ... individuals. The amphibian is being proposed for an Appendix ...
... Boston, Mass. -- A large study from Children,s Hospital Boston ... that samples the entire genome, known as chromosomal microarray analysis, ... related to autism spectrum disorders (ASDs) than standard tests. Publishing ... March 15), the authors urge that CMA become part of ...
... March 10, 2010 Using a novel light activation technique, ... with only a modest ability to fight specific proteins into ... "warhead" molecule capable of inactivating nearby proteins when triggered by ... by providing researchers with a new set of research tools ...
Cached Biology News:Potential CITES trade ban for rare salamander underscores wildlife e-commerce 2A better genetic test for autism 2A better genetic test for autism 3Light activated 'warhead' turns modest molecules into super protein killers 2Light activated 'warhead' turns modest molecules into super protein killers 3
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Rabbit polyclonal to Oct2, prediluted ( Abpromise for all tested applications). entrezGeneID: 5452 SwissProtID: P09086...
Anti-Mouse Reticular Fibroblast, Purified (Clone ER-TR7) (rat IgG2a)...
Mouse monoclonal [2Q2147] to Aequorin ( Abpromise for all tested applications)....
Biology Products: